Annual reportSep 2026
Sep 2026 · Annual Report (Weblink) 9 Sep - 20th AGM on September 30, 2026; dividend record date September 23, 2026; e-voting September 26-29.
Source: Bse
HALEOS LABS LIMITED (HALEOSLABS)
Small CapPharma stocks · Small cap · NSE
HALEOS LABS LIMITED operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
90Strong Bullfull bull SMA stack · SMA20 +3.7% / mo · MACD + · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 84
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
HALEOSLABSD candles · FIT view+16.4%Latest close ₹1583.80 on 2026-10-21
Daily history is available from 2025-11-26; the requested 1Y window is partially covered.
Bar
+2.4%
RSI
62
MACD hist
0.51
52W pos
72%
2026-10-21O ₹1546.00H ₹1615.00L ₹1545.40C ₹1583.80Vol 1,958 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
HALEOSLABSNifty PharmaNifty 500
- HALEOSLABS
- +0.8%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +7.3 pp
Chart stats
21 Oct 2026- From 52W high
- -10.7%
- 52W range position
- 72%
- ATR (14)
- 3.3%
- Volume vs 20D
- 2.19x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹1,450 - ₹1,615
₹1,774
₹1,091.1 - ₹1,774
₹51.6
Latest completed session
20-session average
23.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · OVERVALUED27
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -11.6% · PAT -58.1% YoY
Technical
Strong Bull90
Price trend and sector-relative-strength timing.
Valuation
Legacy model-145.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence64
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -12% YoY · PAT -58% YoY · margin compression
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹72.9 Cr | -11.6% | -2.9% |
| EBITDA | ₹9.1 Cr | -22.1% | +119.2% |
| Operating margin | 12.5% | -169 bps | +696 bps |
| PAT | ₹1.8 Cr | -58.1% | +425.7% |
| PAT margin | 2.5% | -280 bps | +205 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 29.60
- P/B
- 2.19
- EV/EBITDA
- 10.16
- Market Cap
- 468.00Cr
Profitability
- ROE
- 8.44%
- ROCE
- 9.91%
- ROA
- 3.30%
- Dividend Y
- 0.10%
Growth (CAGR)
- Revenue 5Y
- 5.00%
- EPS 5Y
- 5.00%
- Revenue 3Y
- 2.00%
- EPS 3Y
- 20.00%
Balance Sheet
- Debt/Equity
- 0.52
- Interest Coverage
- 6.83×
- Altman Z
- 3.00
- Book Value
- 706.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- 37.00 Cr
- EPS TTM
- 52.31
Shareholding
- Promoter Hold
- 72.10%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 67%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 72.9-2.9% vs prev
Net Profit
₹ CrLatest: 1.8+425.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bullish setupTrend is constructive — long-term uptrend intact. RSI 62.
- Price > SMA20 > SMA50 > SMA200 — full bullish stack.
- SMA20 rising (~3.6% over last month) — short-term momentum positive.
- RSI(14) at 62 — rising, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 11% off 52W high · 45% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
76
RS percentile
Stage 2 UptrendEstablished S2
1M return
+6.5%
3M return
-0.3%
6M return
+19.1%
1Y return
-
RS 1D
+3
RS 20D
+10
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 7.6% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +2.5%.
50-DMA
price above
200-DMA
price above
S2 entered
11 Sept 2026
S2 age
26 trading sessions
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
222 observations
21 Oct 2026Value 127.6+3.92%
RS vs Nifty 500128
Valuation & peers
U-Score 27 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 27 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation5/30
Growth8/25
Quality0/20
Balance Sheet9/15
Cash Flow3/10
Piotroski
8/9 (+5)
Penalties
-3
Raw sum
27
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
27/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 9/15 to the score.
- Growth contributes 8/25 to the score.
Main drags
- Penalty bucket subtracts 3 points.
- Fair-value margin of safety is negative at -145.8%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
29.6
PB
2.2
EV/EBITDA
10.2
ROE
8.4%
ROCE
9.9%
FCF Yield
—
Debt/Equity
0.5
MoS
-145.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
27
Previous: 29 (-2)
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-145.8%
Previous: -138.7%
Score history
12 stored score snapshots. Latest stored move: +1 points.
21 Oct 2026
v4.3-runtime-valuation
28
28
28
28
28
28
28
28
28
28
28
29
Factor attribution
Valuation
5-1
was 6
Balance sheet
9-1
was 10
Modelled fair value
Graham Number
₹911.56
-73.7% MoS
Growth-justified P/E
12.3
Growth-justified Value
₹644.46
-145.8% MoS
PEG
3.70
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ALBERTDAVD
Small
Albert David Limited
Pharmaceuticals
match 167
26
21.7
-0.4%
-23%
OVERVALUED
MEDICAMEQ
Small
Medicamen Biotech Limited
Pharmaceuticals
match 166
18
38.9
4.0%
-521%
OVERVALUED
AAREYDRUGS
Small
Aarey Drugs & Pharmaceuticals Limited
Pharmaceuticals
match 164
15
79.4
2.8%
-1817%
OVERVALUED
AMBALALSA
Small
Ambalal Sarabhai Enterprises Limited
Pharmaceuticals
match 163
41
20.4
12.4%
+30%
WATCHLIST
AMANTA
Small
Amanta Healthcare Limited
Pharmaceuticals
match 161
39
48.2
10.3%
+3%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
HALEOS LABS LIMITED operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
64Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 42nd percentile of the scored universe and 31st percentile within Pharma. Main check: results consistency is weak at 41/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
3 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
42nd percentile
overall median 67 · Pharma: 31st pctile, median 70 · Small: 47th pctile, median 66
Evidence depth
Financial-only
3 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
41
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 72.1%.
- ▸Promoter pledge is zero.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching HALEOS LABS LIMITED
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 29 May - Mrs. Sudeepthi Gopineedi reappointed Whole-time Director for five years from September 2, 2026, subject to shareholders.
Source: Bse
Annual report
Annual report · HALEOS LABS LIMITED has informed the Exchange regarding 'Annual Report (Weblink)'.
Source: Nse
Credit rating
Credit-rating report · HALEOS LABS LIMITED has informed the Exchange about Credit Rating
Source: Nse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual report · SMS Lifesciences India Limited has informed the Exchange regarding 'Annual Report (Weblink)'.
Source: Nse
Investor presentationJul 2025
Jul 2025 · PPT
Source: Bse
Investor presentationJul 2025
Jul 2025 · PPT
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Credit rating
Credit-rating report · SMS Lifesciences India Limited has informed the Exchange about Credit Rating
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.